GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

Trending Topics in Gastroenterology

Explore current gastroenterology questions, clinical answers, and emerging research by topic.

41

Multidisciplinary Lynch Syndrome Clinic: JCO Oncology Practice | August 2026

Introduction: Individuals with Lynch syndrome (LS) require lifelong surveillance for colorectal and upper gastrointestinal cancers, yet adherence to screening recommendations remains suboptimal. This study evaluated whether a dedicated...

42

Acupuncture in Cancer Care: JCO Oncology Practice | July 2026

Introduction: Cancer-related symptoms often persist despite guideline-based pharmacologic treatment, affecting quality of life throughout the cancer journey. This review summarizes the current evidence, safety considerations, and practical implementation...

43

SBRT vs RFA for Oligometastatic Liver Disease: British Journal of Radiology | July 2026

Introduction: Local ablative therapy plays an important role in managing oligometastatic liver disease when surgical resection is not feasible. This review compares stereotactic body radiotherapy (SBRT) and percutaneous...

44

Neoadjuvant Gemcitabine–Cisplatin–Durvalumab for Borderline Resectable Cholangiocarcinoma: Annals of Surgical Oncology | July 2026

Introduction: Borderline resectable cholangiocarcinoma (CCA) carries a poor prognosis because many patients cannot undergo curative surgery. Following the approval of gemcitabine–cisplatin–durvalumab (GCD) in advanced biliary tract cancer, this...

45

dMMR/MSI-H in Locally Advanced Rectal Cancer: European Journal of Cancer | July 2026

Introduction: Immune checkpoint inhibitors have revolutionized the treatment of dMMR/MSI-H rectal cancer, but most patients worldwide continue to receive total neoadjuvant therapy (TNT) as standard care. This international...

46

Dual vs Single Immune Checkpoint Inhibitors in MSI-H/dMMR mCRC: ESMO Gastrointestinal Oncology | September 2026

Introduction: Immune checkpoint inhibitors (ICIs) are the standard first-line treatment for MSI-H/dMMR metastatic colorectal cancer (mCRC). In the absence of direct head-to-head trials, this reconstructed individual patient data...

47

Dual vs Single Immune Checkpoint Blockade in MSI-H Metastatic CRC: ESMO Open | July 2026

Introduction: Immune checkpoint inhibitors (ICIs) have transformed the treatment of microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) metastatic colorectal cancer (mCRC). While pembrolizumab and nivolumab are established treatment options, recent...

48

Three Decades of Progress in Neuroendocrine Liver Metastases: Annals of Surgery | July 2026

Introduction: Neuroendocrine liver metastases (NELM) are a major determinant of morbidity and mortality in patients with neuroendocrine neoplasms. Over the past three decades, advances in imaging, systemic therapies,...

49

FLOT vs CROSS After pCR in Esophageal Adenocarcinoma: JAMA Surgery | July 2026

Introduction: Pathological complete response (pCR) following neoadjuvant therapy is considered a favorable prognostic marker in esophageal adenocarcinoma. However, whether patients achieving pCR derive similar long-term benefit regardless of...

50

KRAS ctDNA Predicts Outcomes After Neoadjuvant Therapy in PDAC: Annals of Surgery | July 2026

Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant...

Previous
145620
Next
GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer